Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Filings indexed 1,720 across all filing types
Latest filing 2024-01-23 Regulatory Filings
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-01-23 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-18 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-17 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-08 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Regeneron Pharmaceuticals, Inc. It reports preliminary unaudited financial results for the fourth quarter of 2023, including net product sales and an acquired in-process research and development charge. The filing includes a corporate update presentation given at the 42nd Annual J.P. Morgan Healthcare Conference. The document is not a full annual or quarterly report but a current report disclosing material events and financial updates. It contains substantive financial data and analysis for a specific quarter but is not a comprehensive interim report. The nature of the filing and the presence of preliminary financial results and corporate update presentation align with the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights. Therefore, the appropriate classification is Earnings Release (ER).
2024-01-08 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.